ALNY · Alnylam Pharmaceuticals Inc
United States · RS rating 13 · As of 2026-10-14
| Price | 224.47 USD |
|---|---|
| 1-day change | +0.3% |
| RS rating (overall / 1M / 3M / 12M) | 13 / 34 / 18 / 13 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 20 / 14 / 17 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -55.4% |
| Sales growth Q/Q | -12.2% |
| Distance from 52-week high | +54.3% |
| Market cap (USD) | $41.9B |